New medications for drug addiction hiding in glutamatergic neuroplasticity.
about
Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brainFuture pharmacological treatments for substance use disordersExercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis.Epigenetics of nicotine: another nail in the coughingThe effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaineNegative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuseGlial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Rapid, transient synaptic plasticity in addictionRole of nucleus accumbens glutamatergic plasticity in drug addictionSerotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorderAnisomycin in the medial prefrontal cortex reduces reconsolidation of cocaine-associated memories in the rat self-administration modelA comprehensive study of sensorimotor cortex excitability in chronic cocaine users: Integrating TMS and functional MRI dataA shift in the role of glutamatergic signaling in the nucleus accumbens core with the development of an addicted phenotypePotential role of N-acetylcysteine in the management of substance use disordersGlial modulators as potential treatments of psychostimulant abuseInteractive Effects of Ethanol and HIV-1 Proteins on Novelty-Seeking Behaviors and Addiction-Related Gene ExpressionNovelty Seeking and Drug Addiction in Humans and Animals: From Behavior to Molecules.PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.Imbalances in prefrontal cortex CC-Homer1 versus CC-Homer2 expression promote cocaine preference.Prefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD).Repeated cocaine treatment enhances HIV-1 Tat-induced cortical excitability via over-activation of L-type calcium channels.Treatment of Gambling Disorders.Using Kalirin conditional knockout mice to distinguish its role in dopamine receptor mediated behaviorsDifferential effects of dorsal hippocampal inactivation on expression of recent and remote drug and fear memory.Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives.The genetics of addiction.Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats.Dorsal medial prefrontal cortex (MPFC) circuitry in rodent models of cocaine use: implications for drug addiction therapies.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans.Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.Blockade of mGluR5 in the nucleus accumbens shell but not core attenuates heroin seeking behavior in rats.An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.New vistas on cannabis use disorder.Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMζ), dopamine, and glutamate receptorsIlluminating circuitry relevant to psychiatric disorders with optogeneticsInteractions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Role of the ventral tegmental area in methamphetamine extinction: AMPA receptor-mediated neuroplasticity.
P2860
Q21129314-DFB65D30-C71B-4584-A70D-24419F5F44C8Q22242633-0BC46A07-1A0D-467C-92C1-7916B6E80AE4Q22251269-C4820EDD-CE46-4B02-BF57-B1C6A62BBE91Q24616185-F7127369-BECE-4AE9-9FE7-B657D56E7EFEQ24631216-34C03EB4-8596-460F-A696-8C6E50F0D238Q26775243-4B3F0511-AA92-41E9-832B-4BA99D43B6A9Q26824667-53D7C558-7DDE-4402-B5B7-0C9477F6D9E0Q26829556-254DA5C4-3A37-4358-BAE1-94C75F9E1097Q26999059-F1DEDCE8-9D10-476C-B60E-DEE89EBC8AC9Q27013753-F6E766BE-66C6-4ECC-99FD-9C1DD5B66EEDQ27015917-D7F00829-5F8F-46AC-98C7-D63C2EC1E1EFQ27305155-D7246D17-D456-4485-B8CB-E6B0BE065C38Q27312072-4E282382-6119-4B9F-9963-18399B92BAE6Q27329409-D1FD1788-1465-423E-838D-8A52592257AAQ28306130-F44B01CC-1F3F-4C83-A3E8-39737A85CD12Q28307030-E212A311-9A35-446B-9186-8C98FF7BD5E6Q30275882-851E79F0-934D-4771-8EE9-E79A55352B76Q30278500-D8571AF0-EE86-4B3E-AA5A-3E6EC3CABC97Q30403978-9B67930B-E9F3-464D-B250-E9693EA1FD65Q30447403-9493990E-1B39-4DA1-8EE9-8D0288AB5138Q30582194-B8E5CBB7-3ADC-4920-B9F5-EB27A504D128Q33605370-ECB0F1D9-1B00-4B09-A39B-8D7862245325Q33698391-20FFAE1C-A52B-4C8E-B810-F39DADB2E587Q33721992-3C22F850-45B1-413A-A97A-DBF9F2C9B506Q33793150-B7358EF5-3FAF-4476-AFE4-0D7C6B850FE8Q33821312-BD747CE4-69CC-46A2-AAE9-61A3AA5BE733Q33911964-348DFF86-9E5A-4BB2-9ED5-109E5D8D5FEAQ34068926-166BA1B9-B4D6-4E1B-8A64-C3B21BD715E9Q34175684-65150127-3D7A-48BD-8A2F-1F103C76BDACQ34253787-C00678C6-54C3-473C-BB03-294111C27C67Q34314041-0D418E9B-F921-4DB7-9437-8FBA360D6B5DQ34407185-75DF5216-655D-4556-A280-9B17FD057E5AQ34613783-46887BA4-A039-450C-8A29-8BAE08BBC711Q34664568-8E0977C5-9F30-4E47-B35D-14781348D2E2Q34675076-2B522432-089A-41CA-B147-3A3A20066EF0Q34681365-2DAF7A95-C4D9-444C-A352-CA77B4D1859EQ34730006-73A282FE-1924-4080-8227-736E21273FAFQ34943448-21599373-E1EA-4795-AEDC-782A2339CD3AQ35007339-D468A234-BBC9-4670-B3B4-E5954FA5D790Q35120472-73F15F22-CFBF-4AAA-944D-067A30BF8C2E
P2860
New medications for drug addiction hiding in glutamatergic neuroplasticity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@ast
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@en
type
label
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@ast
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@en
prefLabel
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@ast
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@en
P2860
P356
P1433
P1476
New medications for drug addiction hiding in glutamatergic neuroplasticity.
@en
P2093
N D Volkow
P W Kalivas
P2860
P2888
P304
P356
10.1038/MP.2011.46
P407
P577
2011-04-26T00:00:00Z